ISO 15378 Certification in Dubai, UAE

ISO 15378 certification is an independent third-party evaluation of the quality management system used to design, manufacture and supply primary packaging materials for medicinal products. It combines the management discipline of ISO 9001 with pharmaceutical good manufacturing practice controls so packaging suppliers can demonstrate consistent control of materials, processes, cleanliness, traceability, inspection, release and continual improvement within the certified scope.

ISO 15378:2017 is the current fourth edition of the international standard for primary packaging materials used with medicinal products. ISO published it in September 2017 and confirmed it in 2023, so the edition remains current. A climate-action amendment was published in 2024 and should be considered when organizations maintain or prepare their management system.

Yes. ISO lists ISO 15378 as a Type A management system standard, which supports independent third-party certification. Organizations involved in the design, manufacture or supply of primary packaging materials for medicinal products can define an appropriate certification scope and demonstrate that their quality and GMP controls are effectively implemented.

The UAE is expanding pharmaceutical, medical-technology and advanced manufacturing capacity, while local manufacturers and importers operate in a highly controlled healthcare supply chain. Primary packaging quality can directly influence product protection, contamination risk, identification, stability and patient confidence. ISO 15378 certification gives packaging suppliers a sector-specific system for controlling those risks and presenting structured evidence to pharmaceutical customers.

The scope can include primary packaging materials and components that are intended to contain, protect or directly interact with medicinal products, depending on the organization’s activities. Examples can include glass, plastics, elastomers, aluminium and related container-closure components. The exact certification scope should reflect what the organization actually designs, manufactures or supplies.

ISO 15378 is focused on primary packaging materials for medicinal products. Secondary packaging activities may still influence the organization’s wider quality system, supplier controls or traceability, but certification scope should not misrepresent secondary packaging as the core subject of ISO 15378 unless those activities form part of a broader certified operation and are clearly described.

ISO 15378 builds on ISO 9001 quality-management principles and adds pharmaceutical packaging controls linked to good manufacturing practice. Organizations familiar with ISO 9001 will recognize leadership, planning, competence, controlled information, performance evaluation, internal audit, management review and improvement, but ISO 15378 applies those disciplines in the more sensitive context of medicinal-product primary packaging.

Good manufacturing practice is central to ISO 15378. Certification looks beyond general quality documentation and considers the controls needed to protect pharmaceutical packaging integrity, including cleanliness, contamination prevention, personnel practices, premises, equipment, process control, identification, traceability, inspection, release, deviation handling and documented evidence.

No. ISO 15378 is particularly relevant to organizations that manufacture or supply primary packaging materials to pharmaceutical companies. The medicinal-product manufacturer may be the customer, while the certified organization can be a specialist packaging producer, component manufacturer or supplier operating within the pharmaceutical packaging supply chain.

No. ISO 15378 certification does not replace UAE legislation, pharmaceutical-facility licensing, product controls, customer specifications, statutory inspections or GMP oversight carried out by the competent authorities. Certification should operate alongside the legal and regulatory framework that applies to the organization, its facility and the products it supplies.

ISO 15378 certification is not universally mandatory for every packaging company in the UAE. Organizations may pursue certification because of pharmaceutical customer expectations, supply-chain qualification, tender conditions, export-market expectations, corporate quality policy, risk management or the need to demonstrate stronger GMP control of primary packaging operations.

The audit examines the management system and operating controls within the agreed scope. Typical areas include leadership, quality planning, facility and equipment control, personnel competence, cleanliness, contamination prevention, material identification, supplier control, production records, process validation where applicable, inspection, traceability, release, nonconforming output, complaints, internal audit, management review and corrective action.

Useful evidence can include approved specifications, material and supplier records, batch documentation, environmental or cleanliness checks, equipment maintenance, calibration, process parameters, inspection and test records, line-clearance evidence, identification and traceability records, deviation investigations, change-control records, complaint handling, internal audit results, management review outputs and corrective actions.

Contamination control is a major concern because primary packaging can directly influence the quality and protection of medicinal products. The organization should understand contamination sources relevant to its materials and processes, maintain suitable premises and practices, control cleaning and handling, protect product during production and storage, and retain evidence showing that those controls are consistently followed.

Traceability supports control of raw materials, production batches, inspections, release status and customer supply. A strong system allows the organization to follow the history of packaging materials and components through defined records, identify affected product when a problem occurs and support efficient investigation, containment, customer communication and corrective action.

Yes. Multi-site certification can be considered where several facilities operate under a defined common management system and central controls are consistently applied. Audit planning will consider site activities, product families, shared functions, process differences, risk, traceability and the way leadership maintains oversight across the proposed certification scope.

Stage 1 is the initial certification-audit stage used to understand the organization, confirm the proposed scope, review the management-system framework, consider site conditions and key GMP controls, check internal review status and determine whether the organization is ready to proceed to the main certification audit.

Stage 2 is the main certification audit. Auditors evaluate how the system works in practice by reviewing production and quality evidence, sampling batch and traceability records, examining facility and equipment controls, interviewing personnel, reviewing nonconformities and complaints, and checking whether internal audit and management review support effective control and continual improvement.

Cost and timing depend on the certification scope, number of sites, employee numbers, product families, process complexity, clean or controlled areas, outsourced activities, level of automation, current management-system maturity and whether ISO 15378 is combined with another certification. A quotation should therefore be based on the real operation rather than a generic fixed fee.

Start by defining the primary packaging products and sites to be certified, mapping material and production flows, reviewing GMP controls, identifying applicable legal and customer obligations, confirming specifications and traceability, checking facility and contamination controls, completing internal audits and management review, closing significant gaps and then planning Stage 1 and Stage 2 certification audits.